Pairs glucagon receptor agonism with GLP-1 receptor agonism. The glucagon arm targets hepatic lipid handling and energy expenditure, which has driven particular interest in metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity.
Phase 2 reported weight reduction and improvement in MASH histology endpoints. Phase 3 ongoing. Not established.
Not approved. Investigational.
Under investigation. Gastrointestinal effects and heart-rate increases reported. Human safety not established.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.